Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Spinoffs Could Come From Pharma’s Acquisition-Based R&D Model

This article was originally published in The Pink Sheet Daily

Executive Summary

“Big pharma” will likely continue to rely on licensing or acquiring novel technologies from biotech innovator firms, panelists said at the BayBio 2006 Conference.

You may also be interested in...



Future BIO Global Efforts Include International Relations, Greenwood Says

HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13

Hospira’s Mayne Event: Acquisition Strengthens Oncology Portfolio

Merger will create the leading generic injectable pharmaceutical company in the world.

Leave It To Beaver: Rozerem DTC Campaign Boosts New Rx Share

Takeda sleep aid’s new Rx share has grown more than 50% since campaign began.

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel